Oslo, Norway, 5 February 2026. Reference is made to the stock exchange
announcement by EXACT Therapeutics AS (the "Company", Euronext Growth ticker:
EXTX), a clinical-stage precision medicine company, published at 09:17 today on
5 February 2026.
In the earlier announcement, it was incorrectly stated that the remaining
warrants holders may exercise their warrants within 21 February 2026. The
correct final date for the warrants exercise is 26 February 2026.
About EXACT Therapeutics:
EXACT Therapeutics is a clinical-stage precision medicine company utilizing the
power of ultrasound to activate the proprietary drug PS101 and enhance the
clinical benefit of oncology therapies. PS101 has a unique mode of action and
may be combined with a wide range of therapeutic agents within oncology and
across a multitude of other indications, including brain diseases. EXACT
Therapeutics' shares are traded on Euronext Growth Oslo (EXTX). Further
information may be found here:www.exact-tx.com
For further information, please contact:
Per Walday
CEO EXACT Therapeutics
Email: per.walday@exact-tx.com